| Identification | Back Directory | [Name]
Volitinib | [CAS]
1313725-88-0 | [Synonyms]
HMPL-504
EOS-60799
AZD-6094)
Volitinib
Savolitinib
Savolitinib (AZD6094)
Savolitinib (Volitinib
HMPL-504(AZD6094, Volitinib)
AZD6094,Volitinib, HMPL-504, Savolitinib
1-[(1S)-1-Imidazo[1,2-a]pyridin-6-ylethyl]-6-(1-methyl-1H-pyrazol-4-yl)-1H-1,2,3-triazolo[4,5-b]pyrazine
(S)-1-(1-(imidazo[1,2-a]pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazine
(S)-1-(1-(imidazo[1,2-a] yridine-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazine | [Molecular Formula]
C17H15N9 | [MDL Number]
MFCD28359096 | [MOL File]
1313725-88-0.mol | [Molecular Weight]
345.36 |
| Chemical Properties | Back Directory | [Melting point ]
205-207°C | [density ]
1.55±0.1 g/cm3(Predicted) | [storage temp. ]
-20°C Freezer | [solubility ]
DMSO (Slightly), Methanol (Slightly) | [form ]
Solid | [pka]
5.67±0.50(Predicted) | [color ]
Pale Beige | [CAS DataBase Reference]
1313725-88-0 |
| Hazard Information | Back Directory | [Description]
Savolitinib selectively inhibits the MET receptor, blocking the PI3K/AKT/MAPK-signaling
pathway as well as downregulating MYC. | [Uses]
Savolitinib is a potent and highly selective c-Met inhibitor. Savoltinib demonstrated anti-tumor efficacy in a panel of cMet-dysregulated gastric cancer PDX models. Savolitinib also demonstrated good antitmuor activities. | [Clinical Use]
It is currently being evaluated
in phase I clinical trials in combination with EGFR TKIs in NSCLC patients. | [storage]
Store at -20°C |
|
|